Sickle cell disease affects about 100,000 people in the United States, most commonly black Americans, according to the U.S. Centers for Disease Control and Prevention.
Luckily, we are seeing more and more progress in treatments for management such as this new clinical trial that shows an FDA-approved supplement reduces episodes of severe pain in people with sickle cell disease.
Endari, a medicine-grade version of the dietary supplement L-glutamine, reduced sickle cell patients’ number of acute pain crises by 25 percent compared with a placebo, the researchers found.
In addition, the supplement reduced hospitalizations by one-third.
“People who were on glutamine did a lot better than those patients who were on